

Meeting Minutes: Drug Formulary Committee

Date & Time: November 20, 2019; 5:30-9 PM
Minutes prepared by: Hind Douiki and Dave Hoang
Location: Elmer Andersen Building, Room 2380, 540 Cedar Street, St. Paul, MN 55101

Attendance

- Members in attendance: Margaret Artz, RPh., PhD.; Monica Brands, RPh.; Kyle Lehenbauer, MD.; Kathryn Lombardo, MD.; Stacey Ness, PharmD.; James Phillips, MD.; Kelly Ruby, PharmD.; Stuart Williams, J.D.; Mary Mescher Benbenek, APRN, PhD.; Ramona Powell, PharmD.
- Members absent: Al Heaton, RPh.; Michael Sprehe, MD.
- DHS staff present: Dave Hoang, PharmD., MBA; Chad Hope, PharmD.
- Others in attendance: Hind Douiki, PharmD.; Ariane Casey, PharmD.

Report of the Chair

- No new report from the Chair

Approval of Minutes

- Minutes from the August 2019 meeting were reviewed and approved.

DHS Housekeeping

- Policy Review and Update
 - Dave indicated that, in an effort to conserve resources, the committee members' binders will not be including printed clinical documents going forward. Instead, five copies of the clinical documents will be made available at the DFC meeting (3 copies for the DFC member to reference during the meeting and 2 copies for the public to view). Proposed PA criteria sheets will continue to be available in committee members' binders and public binders.
 - DHS is considering placing a deadline for providing written testimony to DFC members prior to the meeting in order to provide adequate time for printing
- DFC Plans for 2020
 - Dave inquired if any additional committee member(s) can attend the January 2020 meeting because the number of members who confirmed attendance was not sufficient to establish a quorum.
 - Dave informed DFC members about a change in the food vendor and asked the members to complete a menu form for the next meeting.
 - Dave presented a 2020 tentative agenda for the review of Uniform Preferred Drug List

Old Business

Update on 2019-2020 RSV season

- Synagis – Dave provided an update on the 2019-2020 RSV season and indicated that Synagis PA criteria reflects current AAP clinical guidelines

New Specialty Drugs for Continued PA

- The committee discussed Zolgensma and recommended to the department by a unanimous vote that Zolgensma remain on PA with no changes to the proposed PA criteria.

New Business

Existing Specialty Drugs for Continued PA

- The committee discussed Spinraza and recommended to the department by a unanimous vote that Spinraza remain on PA with no changes to the proposed PA criteria.

New Specialty Drugs for Continued PA

- The committee discussed Piqray and recommended to the department by a unanimous vote that Piqray remain on PA with no changes to the proposed PA criteria.
- The committee discussed Egaten and recommended to the department by a unanimous vote that Egaten remain on PA with no changes to the proposed PA criteria.
- The committee discussed Polivy and recommended to the department by a unanimous vote that Polivy remain on PA with no changes to the proposed PA criteria.
- The committee discussed Sunosi and recommended to the department by a unanimous vote that Sunosi remain on PA, with the following revisions to the criteria:
 1. Addition of the following criterion to the Approval Criteria: “Patient will not be taking Sunosi concomitantly with pitolisant or with sodium oxybate”
 2. Change of bullet #11 to the following: “Patient must have tried and failed an adequate trial of modafinil for at least 3 months”
 3. Addition of the following sub-bullet to bullet #12: “If prescribed a BiPAP machine, the patient must use it for at least 4 hours daily”
- The committee discussed Xpovio and recommended to the department by a unanimous vote that Xpovio remain on PA with no changes to the proposed PA criteria.

- The committee discussed Nubeqa and recommended to the department by a unanimous vote that Nubeqa remain on PA, with the replacement of “disease” in the second bullet to “prostate cancer”.

Preferred Drug List Review

1. Analgesics, Narcotics Long - The committee discussed the Analgesics, Narcotics Long class and recommended the following to the department by a unanimous vote:
 - a. Butrans to be removed from the PDL
 - b. Belbuca to change from nonpreferred to preferred
 - c. Oxycontin to remain nonpreferred
 - d. Oxycodone ER to remain nonpreferred
 - e. Xtampza ER to remain nonpreferred
2. Immunosuppressives, Oral - The committee discussed the Immunosuppressives, Oral class and recommended the following to the department by a unanimous vote:
 - a. Prograf Granules Pack to be removed from the PDL
 - b. Sirolimus to remain as nonpreferred
3. NSAIDs - The committee discussed the NSAIDs class and recommended the following to the department by a unanimous vote:
 - a. Ibuprofen (Rx) to be added to the PDL as preferred
 - b. Diclofenac Gel to change from nonpreferred to preferred
4. Stimulants And Related Agents - The committee discussed the Stimulants And Related Agents class and recommended the following to the department by a unanimous vote:
 - a. Jornay PM to be added to the PDL as nonpreferred
 - b. Adhansia XR to be added to the PDL as nonpreferred
 - c. Provigil to be removed from the PDL
 - d. Modafinil to be removed from the PDL

Adjournment

- The meeting was adjourned at approximately 8:32 PM Central Time.